Research Topics
| A AvilesSummaryAffiliation: National Medical Center Publications
|
Detail Information
Publications
Nasal NK/T-cell lymphoma with disseminated disease treated with aggressive combined therapyAgustin Avilés
Oncological Research Unit, Oncology Hospital, National Medical Center, IMSS, Mexico
Med Oncol 20:13-7. 2003..The use of intensive more specific chemotherapy and high dose of local radiotherapy, appear to be an excellent therapeutic approach with improvement in EFS and OS...- Radiotherapy versus combined therapy in early stages with bulky disease aggressive malignant lymphomaAgustin Avilés
Oncology Research Unit, Oncology Hospital, National Medical Center, IMSS, Mexico, DF, Mexico
Hematology 8:7-10. 2003..We conclude that combined therapy appear to be superior in patients with early stages and bulky disease in patients with aggressive malignant lymphoma... - Biological modifiers as cytoreductive therapy before stem cell transplant in previously untreated patients with multiple myelomaA Aviles
Oncology Research Unit and Department of Hematology, Oncology Hospital National Medical Center, Mexico, D F Mexico
Ann Oncol 16:219-21. 2005..The use of biological modifiers has not been considered in this situation. We developed a new cytoreductive regimen, in an attempt to retain clinical efficacy but reduce toxicity... - Lack of prognostic factors in follicular lymphomaAgustin Avilés
Oncology Research Unit, The Oncology Hospital, National Medical Center, IMSS, Mexico, DF, Mexico
Leuk Lymphoma 44:143-7. 2003.... - Treatment of advanced Hodgkin's disease: EBVD versus intensive brief chemotherapyAgustin Avilés
Oncology Research Unit, Oncology Hospital, National Medical Center, IMSS, Mexico, D F, Mexico
Leuk Lymphoma 44:1361-5. 2003..In the present single center trial, intensive chemotherapy did not appear to have better results when compared with standard chemotherapy in patients with advanced Hodgkin's disease... - Maintenance therapy with interferon-alpha 2b, cyclophosphamide, and prednisone in aggressive diffuse large cell lymphomaAgustin Avilés
Oncology Research Unit, Oncology Hospital, National Medical Center, IMSS, Mexico, D F Mexico
Stem Cells Dev 13:205-9. 2004..We conclude that use of maintenance therapy combining interferon-alpha 2b, cyclophosphamide, and prednisone is not useful in patients with aggressive lymphoma if they had been treated with aggressive combined chemotherapy... - The role of surgery in primary gastric lymphoma: results of a controlled clinical trialAgustin Avilés
Oncology Research Unit, Oncology Hospital, National Medical Center, IMSS, Mexico
Ann Surg 240:44-50. 2004.... - Gemcitabine and cisplatin in refractory malignant lymphomaAgustin Avilés
Oncology Research Unit, Mexican Social Security Institute, Mexico City, Mexico
Oncology 66:197-200. 2004..We performed a pilot study to evaluate the effect of the high-dose gemcitabine-cisplatin combination in a brief weekly regimen in the treatment of primary refractory diffuse large cell lymphoma with high or high-intermediate clinical risk... - Adjuvant radiotherapy in stage IV diffuse large cell lymphoma improves outcomeAgustin Avilés
Oncology Hospital, National Medical Center, IMSS, Mexico, DF, Mexico
Leuk Lymphoma 45:1385-9. 2004..Thus, we felt that adjuvant radiotherapy will be considered as part of the initial treatment in this setting of patients... - Intensive chemotherapy in the treatment of aggressive diffuse large B-cell lymphoma: malignant lymphomaAgustin Avilés
Oncology Research Unit, Oncology Hospital, National Medical Center, IMSS, Mexico, D F Mexico
Med Oncol 21:269-72. 2004..The intensive CEOP-Bleo regimen with increasing doses of cyclophosphamide and epirubicin is a useful and well-tolerated regimen in the treatment of poor prognosis diffuse large B-cell lymphoma... - Combined therapy in the treatment of primary mediastinal B-cell lymphoma: conventional versus escalated chemotherapyA Aviles
Research Unit in Oncology Diseases, Oncology Hospital, National Medical Center, Instituto Mexicano del Seguro Social, Apartado Postal 7 1220, 06700, Mexico D F, Mexico
Ann Hematol 81:368-73. 2002..Patients with pleural or pericardial effusion are considered at high risk for failure with the actual programs of treatment and probably will be considered for experimental therapeutic approaches... - Large bowel lymphoma: an analysis of prognostic factors and therapy in 53 patientsAgustin Avilés
Department of Hematology, Oncology Hospital, National Medical Center, I M S S, Mexico D F, Mexico
J Surg Oncol 80:111-5. 2002.... - Novel therapy in multiple myelomaAgustin Avilés
Oncology Research Unit, Department of Hematology, Oncology Hospital, National Medical Center, IMSS, Mexico, D F Mexico
Invest New Drugs 23:411-5. 2005..Controlled clinical trials comparing with conventional chemotherapy will be conducted to define the role of this therapeutic approach... - Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapyAgustin Avilés
Oncology Research Unit, Oncology Hospital, National Medical Center, IMSS, Mexico, D F Mexico
Leuk Lymphoma 46:1023-8. 2005..Thus, we would not recommend use of the drug in Hodgkin's disease. ERNA and echocardiogram are early detection tests for cardiac toxicity and can be employed in surveillance studies... - Interferon alpha 2b as maintenance therapy improves outcome in follicular lymphomaAgustin Avilés
Oncology Research Unit, Oncology Hospital, National Medical Center, IMSS, Mexico, D F Mexico
Leuk Lymphoma 45:2247-51. 2004..The use of aggressive chemotherapy and maintenance therapy with interferon alpha 2b in follicular lymphoma improved outcome; more than 60% of patients remain alive free of disease at longer follow-up... - Mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach: results of a controlled clinical trialAgustin Avilés
Oncology Research Unit, National Medical Center, IMSS, Mexico
Med Oncol 22:57-62. 2005..Thus considered, chemotherapy alone is an effective and safe therapeutic approach in this setting of patients. Surgery or radiotherapy will be reserved to patients that are not candidates for chemotherapy... - Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in uteroA Aviles
Oncology Diseases Research Unit, Oncology Hospital, National Medical Center, IMSS, Mexico, D F, Mexico
Clin Lymphoma 2:173-7. 2001.... - Treatment of refractory Hodgkin's disease with modified Stanford V programA Aviles
Oncological Research Unit, Oncology Hospital, National Medical Center, IMSS, Mexico, DF
Med Oncol 18:261-7. 2001..A controlled clinical trial in untreated patients comparing the Stanford program with standard chemotherapy is warranted to define the role of this therapeutic option in patients with Hodgkin's disease... - Spinal cord compression as a primary manifestation of aggressive malignant lymphomas: long-term analysis of treatments with radiotherapy, chemotherapy or combined therapyAgustin Avilés
Research Unit in Oncological Diseases, Oncology Hospital, National Medical Center, IMSS, Mexico, DF, Mexico
Leuk Lymphoma 43:355-9. 2002..The use of combined therapy improves the outcome in this group of patients, and so it should be considered the treatment of choice... - Interferon alfa 2b as maintenance therapy in poor risk diffuse large B-cell lymphoma in complete remission after intensive CHOP-BLEO regimensA Aviles
Department of Hematology, Oncology Hospital, National Medical Center, IMSS, Mexico, DF, Mexico
Eur J Haematol 66:94-9. 2001.... - Rituximab in the treatment of refractory follicular lymphoma -- six doses are better than fourA Aviles
Research Unit in Oncology Diseases, National Medical Center, IMSS, Mexico, D F Mexico
J Hematother Stem Cell Res 10:313-6. 2001..However, the number is too small to drawn definitive conclusions, and more clinical trials are necessary to determine if four of six doses of anti-CD20 therapy are better in this setting of patients... - Second lethal events associated with treatment for Hodgkin's disease: a review of 2980 patients treated in a single Mexican instituteA Aviles
Oncology Disease Research Unit, Oncology Hospital, National Medical Center, IMSS, Mexico, D F Mexico
Leuk Lymphoma 39:311-9. 2000.... - Treatment of acquired immunodeficiency syndrome-related lymphoma with a standard chemotherapy regimenA Aviles
Department of Hematology, Oncology Hospital, National Medical Center, Mexico, D F, Mexico
Ann Hematol 78:9-12. 1999..The use of a standard regimen appears to be an adequate therapeutic approach in this group of patients... - Angiocentric nasal T/natural killer cell lymphoma: a single centre study of prognostic factors in 108 patientsA Aviles
Departament of Hematology, Oncology Hospital, National Medical Center, Mexico
Clin Lab Haematol 22:215-20. 2000..There was no evidence that the international prognostic index (IPI) was applicable in these patients and it appears that angiocentric T/NK cell lymphoma is an independent prognostic factor itself... - Late lethal events in patients with diffuse large B cell lymphoma: a review of 714 patients treated in a single centreA Aviles
Department of Hematology, Hospital National Medical Center IMSS, Mexico, DF, Mexico
Leuk Lymphoma 42:631-7. 2001..The proposed modifications of therapy many indeed be useful to avoid or diminish these complications in the future... - High dose chemotherapy with G-CSF in refractory Hodgkin's diseaseA Aviles
Department of Hematology, Oncology Hospital, National Medical Center México, DF Mexico
Leuk Lymphoma 36:139-45. 1999.... - Long-term evaluation of cardiac function in children who received anthracyclines during pregnancyA Aviles
Oncology Research Unit and Department of Hematology, Oncology Hospital National Medical Center, IMSS, Mexico, D F Mexico
Ann Oncol 17:286-8. 2006..The outcome of children that received antracyclines during pregnancy, including during the first trimester, remain unknown because long-term follow-up is not available...